Helen Creedon

Edinburgh, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK.

TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK.

Journal: BMJ open

Published: December 26, 2024

Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma.

Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 10, 2024

Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.

Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.

Journal: Gynecologic oncology

Published: December 15, 2022

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.

Journal: Scientific reports

Published: November 30, 2022

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.

Journal: Breast cancer research and treatment

Published: May 03, 2019

Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis.

Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis.

Journal: Cancer research

Published: May 26, 2017

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.

Journal: Oncotarget

Published: December 09, 2015

Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.

Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.

Journal: Disease models & mechanisms

Published: September 02, 2015

Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.

Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.

Journal: Biochemical Society transactions

Published: August 12, 2014

Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.

Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.

Journal: The Journal of pathology

Published: October 01, 2012

Src kinase inhibitors: promising cancer therapeutics?

Src kinase inhibitors: promising cancer therapeutics?

Journal: Critical reviews in oncogenesis

Published: April 05, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026